Newsroom

AUSTIN, Texas--(BUSINESS WIRE)--Empery Digital Inc. (NASDAQ: EMPD) (the “Company” or “Empery Digital”) announced today that the Company’s Board of Directors (the “Board”) approved an amendment to the Company’s stockholder rights plan (the “rights plan”) to accelerate the expiration date to the close of business on July 6, 2026. The rights plan was scheduled to expire on February 2, 2027. In deciding to terminate the rights plan, the Board determined that maintaining the rights plan is no longer...

MELBOURNE, Fla.--(BUSINESS WIRE)--L3Harris Technologies (NYSE: LHX) will release its second quarter 2026 financial results after the market closes on Wednesday, July 29, 2026.The company will then host an earnings call on Wednesday, July 29, 2026, at 5 p.m. ET. Participants are encouraged to listen via webcast at L3Harris.com. A replay of the call will also be available on L3Harris.com following the event.About L3Harris TechnologiesL3Harris is the Trusted Disruptor in defense tech. With customer...

TOKYO--(BUSINESS WIRE)--LogProstyle Inc. (NYSE American: LGPS) (the “Company” or “LogProstyle”), headquartered in Minato-ku, Tokyo, Japan, announced today that it will release its financial results for the full fiscal year ended March 31, 2026 (“FY2026”) at 8:00 a.m. Eastern Time on July 13, 2026. In connection with the results, the Company will make available a pre-recorded presentation reviewing its FY2026 financial and operational performance. The presentation will be accessible on the Compa...

SAN FRANCISCO--(BUSINESS WIRE)--Perpetuals.com Ltd (Nasdaq: PDC), anunció hoy que UpsideOnly, su plataforma de negociación libre de riesgo y predicción de mercados, ha registrado un fuerte aumento en el número de nuevos usuarios, superando el importante hito de 100 000 operadores apenas unas semanas después de su lanzamiento, el pasado 19 de mayo. UpsideOnly permite a los usuarios predecir la dirección de los mercados globales de acciones, materias primas, divisas y criptomonedas sin realizar o...

印度达尔瓦德--(BUSINESS WIRE)--(美国商业资讯)-- Shilpa Medicare Limited宣布，其全资子公司Shilpa Biologicals Private Limited已与Orion Corporation签署一项合作开发及供应协议，双方将共同开发并供应静脉注射（IV）纳武利尤单抗生物类似药。该产品以全球应用最广泛的肿瘤免疫治疗药物之一为参照药，双方将携手推动其在欧洲市场的开发与供应，进一步提升欧洲患者获得这一重要治疗方案的可及性。 纳武利尤单抗的问世开启了肿瘤免疫治疗新时代，显著改善了黑色素瘤、肺癌等多种癌症患者的治疗前景。随着其原研药在欧洲即将失去市场独占权，双方此次合作旨在推出一款采用符合欧盟药品生产质量管理规范（EU-GMP）标准生产的高品质纳武利尤单抗生物类似药，使更多欧洲患者能够获得这一重要免疫治疗药物，同时减轻医疗体系负担。根据IQVIA/IMS的数据，纳武利尤单抗2025年在欧洲实现销售额约41亿美元，进一步凸显了这一市场的巨大潜力。 根据协议，Orion将拥有该纳武利尤单抗生物类似药在欧洲市场的独家注册、商业化推广、分销及销售权。S...

TORONTO--(BUSINESS WIRE)--À une période de l’année où les Canadiens optent pour des cocktails légers et rafraîchissants pour rehausser leurs rassemblements estivaux, GREY GOOSE® Vodka lance Le Melon Ace™. Créé en partenariat avec l’Omnium Banque Nationale présenté par Rogers, ce cocktail exclusif au Canada a été nommé cocktail officiel des tournois. Tout au long des tournois à Toronto et à Montréal cette année, il sera possible de déguster ce cocktail qui allie l’énergie du tennis de classe mon...

TORONTO--(BUSINESS WIRE)--As Canadians embrace lighter, refreshing tasting cocktails to elevate summer hosting, GREY GOOSE® Vodka is introducing Le Melon Ace™, a Canada-exclusive serve created in partnership with the National Bank Open presented by Rogers and named the tournament’s official cocktail. Available throughout this year’s tournament in Toronto and Montréal, the cocktail connects the energy of world-class tennis with the evolving rituals of summer entertaining. Inspired by iconic cour...

AUSTIN, Texas--(BUSINESS WIRE)--DBGI Corp. (NASDAQ:DBGI) a publicly traded company specializing in eCommerce and fashion today announced that announces that the Company has retained the law firm of Christian Attar, a recognized market manipulation and naked short litigation firm located in Houston, Texas, to an investigation of any potential naked short selling or other market manipulation of common shares of Digital Brands Group. Additionally, the Company engaged Shareholder Intelligence Servi...

DHARWAD, India--(BUSINESS WIRE)--Shilpa Medicare Limited ha annunciato che la sua filiale totalmente controllata, Shilpa Biologicals Private Limited, ha sottoscritto un accordo di sviluppo congiunto e fornitura con Orion Corporation per un biosimilare di nivolumab per via endovenosa (IV), basato su una delle immunoterapie antitumorali più diffuse al mondo, per ampliare l’accesso dei pazienti in tutta Europa. Nivolumab ha contribuito a inaugurare l’era dell’immuno-oncologia, trasformando le pros...

DHARWAD, India--(BUSINESS WIRE)--Shilpa Medicare Limited heeft bekendgemaakt dat haar volledige dochteronderneming, Shilpa Biologicals Private Limited, een overeenkomst voor gezamenlijke ontwikkeling en levering heeft gesloten met Orion Corporation. Deze overeenkomst betreft een biosimilar van intraveneus (IV) nivolumab, gebaseerd op een van ’s werelds meest gebruikte immuuntherapieën tegen kanker, om de toegang voor patiënten in heel Europa te vergroten. Nivolumab heeft het tijdperk van de imm...